Skip to main content

Table 1 Clinical and pharmacokinetic characteristics of patients.

From: Micafungin concentrations 100 mg daily in plasma and burn eschars in patients with severe burn injuries

Patient % burned TBSA % FT ABSI MCF dose (mg/kg body weight) Plasma Cmax/Cmin after first dose (μg/ml) Plasma C/max/Cmin at steady state (μg/ml) Burn easchar tissue on day 5 (μg/ml) Days from admission to the start of MCF SOFA at the beginning of MCF LOS in BUCU (days)
1 35 20 9 1.3 8.6/0.8 7.4/1.0 2.3 38 1 75
2 40 35 8 2.0 8.5/1.1 9.4/1.8 <LQ 15 6 23
3 23 16 8 1.3 6.4/0.8 10.3/1.2 <LQ 12 2 17
4 70 40 12 1.1 3.9/0.5 4.5/0.8 0.4 8 6 43
5 23 12 7 1.3 7.5/1.8 8.0/1.4 0.6 10 5 19
6 70 60 11 1.2 3.4/0.5 5.0/0.9 1.5 12 5 70
7 80 70 12 1.1 3.8/0.4 4.0/0.4 0.2 34 2 61
8 60 50 10 1.4 4.8/0.5 4.3/1.0 0.2 34 2 90
9 44 34 10 1.3 4.5/1.1 9.1/2.3 0.2 8 6 34
10 34 28 9 1.3 4.1/0.7 5.4/1.0 0.7 10 5 35
Median 42 34.5 9.5 1.3 4.7/0.7 6.4/1.0 0.5 12 5.0 39
IQR 31.3 to 70.0 19.0 to 52.5 8 to 11.3 1.1 to 1.4 3.9 to 7.5/0.5 to 1.1 4.5 to 9.1/0.9 to 1.4 0.3 to 1.1 9.5 to 19.8 3.5 to 5.6 22.7 to 71.3
  1. ABSI, Abbreviated Burn Severity Index; BICU, burn intensive care unit; FT, full thickness; IQR, interquartile range; LOS, length of hospital stay; LQ, limit of quantification (<0.1 μg/ml); SOFA, Sequential Organ Failure Assessment; TBSA, total body surface area.